Retatrutide for insulin resistance

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 May 2025: Trial registered, NCT06982859
  2. 2 Jun 2025: Trial started, NCT06982859

The trials

NCT06982859: A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

State
Under way
Phase
Phase 1
People
95 planned
Started
2 Jun 2025
Primary completion
Jan 2027
Arms
Retatrutide
Results
None posted
  1. 21 May 2025: Trial registered
  2. 2 Jun 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Retatrutide (LY3437943).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.